We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.05 | 0.03% | 145.50 | 145.97 | 144.48 | 145.35 | 4,075,344 | 00:58:38 |
Beasley Allen Attorney: Women are saying ‘enough is enough’
Women who previously filed lawsuits against Johnson & Johnson for damages caused by its defective talc products have filed a class action lawsuit in U.S. District Court in New Jersey accusing J&J of engaging in a series of fraudulent maneuvers designed to prevent cancer victims and their families from receiving fair compensation for their health-related claims.
The lawsuit alleges three specific mileposts in Johnson & Johnson’s fraudulent strategy:
According to the lawsuit, these fraudulent steps to use the bankruptcy courts to limit liability for talc claims resulted in delays of scheduled trials or other forms of resolution to the class for more than two years. The company has since announced its intent to pursue a “pre-packaged” bankruptcy in a third attempt to reduce liabilities.
The plaintiffs in the proposed class are represented by attorneys with the law firms of Ashcraft & Gerel, Bailey Glasser, Beasley Allen, Burns Charest, Golomb Legal, and Levin Papantonio Rafferty.
“Johnson & Johnson is playing a dark game of chess with this country's financial and judicial systems. With a net worth of nearly $400 billion, this corporation has deliberately manipulated assets to sidestep its obligations to ovarian cancer victims and in so doing has robbed them of true and rightful justice,” says Mike Papantonio of Pensacola, Florida-based Levin Papantonio Rafferty.
“The bad faith that the courts found in ruling against J&J in the two previous bankruptcies applies to every action the company has taken during the past three years,” says Andy Birchfield of Alabama-based Beasley Allen. “The individuals bringing this class action are shining a bright light on the entire series of dubious, unlawful and hypocritical ploys J&J has been following, and they’re saying enough is enough.”
Reliable and consistent scientific studies show that regular exposure to talc results in a 30% to 60% increased risk of ovarian cancer. Despite corporate denials, it’s been shown that J&J’s talc also contains asbestos. Asbestos causes mesothelioma and ovarian cancer, both of which are often fatal. Evidence presented in litigation against Johnson & Johnson reveals that the company was aware that its product contained asbestos and continued to sell it for another 50 years.
Last week, researchers from the National Institutes of Health published a study in the Journal of Clinical Oncology which found a significant and positive association between genital talc use and ovarian cancer, with the highest risks observed in frequent and long-term users. The study involved more than 50,000 women from the Sister Study cohort study which examined the genetic predisposition to hormone-related cancers.
“As the scientific record grows even stronger, J&J’s repeated denials of the dangers of genital talc use, attempts to shirk the company’s responsibility to cancer victims and abuse of the bankruptcy system become even more egregious and tragic,” says Michelle Parfitt of Ashcraft & Gerel.
The defendants in the proposed class action include both J&J corporate entities and individual executives, including J&J Chief Executive Officer Joaquin Duato and Kenvue Chief Executive Officer Thibaut Mongon.
The case is Rebecca Love et al. v. LLT Management LLC et al., Case No. 3:24-cv-06320 filed in the U.S. District Court for the District of New Jersey.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240522525674/en/
Media Contact: Mike Androvett mike@androvett.com 800-559-4534
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions